Literature DB >> 27900478

Dexamethasone intravitreal implant in retinal vein occlusion:real-life data from a prospective, multicenter clinical trial.

Dan Călugăru1, Mihai Călugăru2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27900478     DOI： 10.1007/s00417-016-3559-8

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  9 in total

1.  Pro-permeability Factors After Dexamethasone Implant in Retinal Vein Occlusion; The Ozurdex for Retinal Vein Occlusion (ORVO) Study.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Am J Ophthalmol       Date:  2015-10-23       Impact factor: 5.258

2.  Retreatment with Ozurdex for macular edema secondary to retinal vein occlusion.

Authors:  Gabriel Coscas; Albert Augustin; Francesco Bandello; Marc D de Smet; Paolo Lanzetta; Giovanni Staurenghi; Maria Cristina Parravano; Patricia Udaondo; Elad Moisseiev; Gisele Soubrane; Yossi Yatziv; Anat Loewenstein
Journal:  Eur J Ophthalmol       Date:  2013-10-14       Impact factor: 2.597

Review 3.  TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations.

Authors:  K Bailey Freund; Jean-François Korobelnik; Robert Devenyi; Carsten Framme; John Galic; Edward Herbert; Hans Hoerauf; Paolo Lanzetta; Stephan Michels; Paul Mitchell; Jordi Monés; Carl Regillo; Ramin Tadayoni; James Talks; Sebastian Wolf
Journal:  Retina       Date:  2015-08       Impact factor: 4.256

4.  Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Am J Ophthalmol       Date:  2015-03       Impact factor: 5.258

5.  Intravitreal bevacizumab in acute central/hemicentral retinal vein occlusions: three-year results of a prospective clinical study.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  J Ocul Pharmacol Ther       Date:  2014-10-14       Impact factor: 2.671

6.  Normative data for macular thickness by high-definition spectral-domain optical coherence tomography (spectralis).

Authors:  Sandeep Grover; Ravi K Murthy; Vikram S Brar; Kakarla V Chalam
Journal:  Am J Ophthalmol       Date:  2009-05-09       Impact factor: 5.258

7.  Normal macular thickness measurements in healthy eyes using Stratus optical coherence tomography.

Authors:  Annie Chan; Jay S Duker; Tony H Ko; James G Fujimoto; Joel S Schuman
Journal:  Arch Ophthalmol       Date:  2006-02

8.  Onset and duration of visual acuity improvement after dexamethasone intravitreal implant in eyes with macular edema due to retinal vein occlusion.

Authors:  Baruch D Kuppermann; Julia A Haller; Francesco Bandello; Anat Loewenstein; Jenny Jiao; Xiao-Yan Li; Scott M Whitcup
Journal:  Retina       Date:  2014-09       Impact factor: 4.256

9.  Dexamethasone intravitreal implant in retinal vein occlusion: real-life data from a prospective, multicenter clinical trial.

Authors:  Nicole Eter; Andreas Mohr; Joachim Wachtlin; Nicolas Feltgen; Andrew Shirlaw; Richard Leaback
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-07-26       Impact factor: 3.117
  9 in total
  3 in total

1.  Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the Ranidex study.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-07-25       Impact factor: 3.117

2.  Reply to a letter to the editor: Dexamethasone intravitreal implant in retinal vein occlusion: real-life data from a prospective, multicenter clinical trial.

Authors:  Nicole Eter; Andreas Mohr; Joachim Wachtlin; Nicolas Feltgen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-12-13       Impact factor: 3.117

3.  Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in Chinese patients: randomized, sham-controlled, multicenter study.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-02-04       Impact factor: 3.117
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.